Building a workplace where diverse professionals can thrive
First written in FY2023. . Latest entry: FY2026.
- FY2026Human capital performance metrics updatedAnnual report
「The company operates a flextime system with core hours and has established a workplace environment that supports individual work-life balance through measures including encouraging the use of paid leave (actual average utilization rate of approximately 83%), supporting employees’ return to work after parental leave (actual return-to-work rate of 100% since the company’s establishment) and encouraging men to take childcare leave (actual utilization rate of 100% most recently).」
The company disclosed an actual average paid-leave utilization rate of approximately 83% and updated its human capital performance metrics together with a 100% return-to-work rate after parental leave and a 100% childcare-leave utilization rate among men. - FY2024Additional disclosure of human capital performance indicatorsAnnual report
「The Company operates a flextime system with core hours and has established an internal environment that supports individual work-life balance through measures including encouraging employees to take paid leave (an average utilization rate of approximately 80%), supporting employees returning to work after maternity leave (a 100% return-to-work rate since the Company's foundation) and encouraging men to take parental leave (a 100% utilization rate most recently).」
In connection with creating a workplace where diverse specialist talent can thrive, the Company disclosed performance indicators including a flextime system, a paid-leave utilization rate of approximately 80%, a 100% return-to-work rate after maternity leave and a 100% parental-leave utilization rate among men. - FY2023First statedAnnual report
「The Company recognizes that contributions from professionals with diverse areas of expertise are essential to its drug discovery business, and that developing its people, including ensuring workforce diversity, and creating a rewarding workplace are particularly important issues.」
For the first time, the Company has explicitly identified the development of diverse specialist talent in its drug discovery business, workforce diversity and the creation of a rewarding workplace as important issues.